Skip to main content

Global Renal Denervation Market forecast 40% CAGR driven by hypertension prevalence 2027

 

Global Renal Denervation Market estimated at $140 Million (2022), is growing at a healthy CAGR of 40% y 2027. The market growth is driven by the growing geriatric population, the rising prevalence of hypertension, and venture capital funding. The U.S. market is likely to offer high growth opportunities in next 3-5 years.

Resistant hypertension is a blood pressure that remains elevated above target levels despite use of anti-hypertensive medications. About 12-15% of the population treated for high blood pressure suffers from resistant hypertension. Renal denervation is a minimally invasive procedure used to treat resistant hypertension. As the geriatric population is growing, the number of people suffering from hypertension and the resistant hypertension is also growing which is driving the RDN market growth.

Download a free sample report now 👉
https://meditechinsights.com/global-renal-denervation-market/request-sample/

The rising prevalence of hypertension is driving the Renal Denervation Market Growth

According to WHO, currently more than one billion people across the globe are suffering from hypertension which is expected to grow to 1.6 billion by 2025. WHO estimated that less than one in five people have their hypertension under control, either due to non-adherence or resistance to medications. This is leading to growing prevalence of hypertension/resistant hypertension, thereby driving the Renal Denervation market growth.

Lack of long-term clinical data and risks associated with RDN procedure inhibits the Renal Denervation market growth

Though Renal Denervation is perceived as potential treatment for resistant hypertension, it is a relatively new procedure and less data is available on its long-term effects. Owing to the limited clinical evidence, the RDN products are available only for investigational purpose in some of the major markets. For instance, Medtronic’s Symplicity Spyral RDN System’s use is limited only to investigational purpose in the U.S., Japan, and Canada. Further, there are various risks associated with this procedure which limits its use. Some patients experience bradycardia during the procedure. The RF ablation may cause changes to the wall of the arteries, which can sometimes lead to renal artery stenosis. The imaging used during the procedure also has a number of risks. Other complications include tearing in the renal arteries and pseudoaneurysm (a bruise caused by a leaking hole in an artery).

North America to offer high growth opportunities in Renal Denervation Market

From a geographic perspective, Europe is the single largest renal denervation market. This is mainly attributed to the growing aging population, rising prevalence of hypertension, and higher penetration due to commercial availability of RDN products within Europe. The North American market is at nascent stage as the RDN companies are yet to launch the products for commercial use in the region. However, the companies in the RDN market are thriving to introduce their products in the U.S. market and are focusing their efforts on getting the commercial approvals. For instance, Medtronic is likely to publish its results of SPYRAL HTN-ON MED clinical trials for its RDN system in the U.S. in later half of 2022. Further, in March 2022, ReCor Medical (Otsuka) completed subject enrolment for its RADIANCE-II pivotal trial of its Paradise Ultrasound Renal Denervation (uRDN) System for generating clinical trial data to enter the U.S. market.

Some key players operating in the global renal denervation market include Medtronic, Boston Scientific Corporation, St. Jude Medical (Abbott), ReCor Medical (Otsuka), Cordis Corporation, and Terumo Corporation, among others.

Download a sample report for in-depth competitive insights
https://meditechinsights.com/global-renal-denervation-market/request-sample/

Citing the growth potential of Renal Denervation Market, venture capital firms are helping start-ups to expedite their clinical trial efforts

  • In December 2021, SyMap Medical completed financing round of $100 million led by Primavera Capital and VMS Group, with the participation of existing investors Simiao Equity Investment and Sequoia Capital China.
  • In April 2021, China-based renal denervation firm Brattea completed $20 million funding round. The round was led by led by healthcare private equity fund Kuanping Capital.

About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde
 Associate, Medi-Tech Insights
 +32 498 86 80 79
 info@meditechinsights.com 

Comments

Post a Comment

Popular posts from this blog

Global Biotechnology Market to grow at 13–15% CAGR as CRISPR use expands globally by 2029

  The global biotechnology market is set to witness a growth rate of 13-15% in the next 5 years.  Advancements in genetic engineering and genomics; growing demand for biopharmaceuticals; rising incidence of chronic diseases; growth in environmental and agricultural biotechnology; increased investment in R&D; growing demand for synthetic biology; and presence of favorable government initiatives are some of the key factors driving the biotechnology market. Biotechnology is the scientific field that uses biological organisms, systems, or processes to develop products and technologies aimed at improving health, agriculture, environmental sustainability, and industrial efficiency. By applying principles of genetics, molecular biology, and biochemistry, biotechnology enables advancements like genetic engineering, biopharmaceutical development, biofuels, and genetically modified organisms (GMOs). This field is instrumental in producing therapies for diseases, increasing crop r...
Post a Comment
Read more

Global Multi Cancer Early Detection Market expanding 15–20% CAGR through personalized care 2030

  The multi cancer early detection market is expected to grow at a CAGR of around 15-20% during the forecast period.  This growth is primarily due to the rising awareness and increasing demand for early-stage screening tools, especially as cancer rates continue to rise globally, and technological advancements in screening methods. However, high costs and strict regulations can still hinder the market growth.  Multi Cancer Early Detection (MCED) refers to tests designed to detect multiple cancers, often from a single blood sample, unlike traditional methods, which can include multiple diagnostic tests or biopsies. These tests look for signs like DNA methylation patterns or small traces of tumor DNA floating in the bloodstream. The primary goal is early cancer detection, ideally before any symptoms appear, so the overall treatment is more effective and less expensive. Download a free sample report now 👉 https://meditechinsights.com/multi-cancer-early-detection-marke...
Post a Comment
Read more

Global Cell Isolation Market projected to grow at 11% CAGR with R&D in oncology therapies by 2030

  The global cell isolation market is projected to grow at a CAGR of 11% from 2025 to 2030,  driven by rising investments in cell-based research, increasing adoption of cell therapies, and growing demand for biopharmaceutical production. Growth is further supported by technological advancements in isolation methods, increasing R&D activities in regenerative medicine, and expanding clinical applications for isolated cells.  Cell isolation is a fundamental process in life sciences and clinical research, involving the separation of specific cell types from complex biological samples. The market is expanding due to growing applications in stem cell research, cancer biology, immunology, and personalized medicine. Additionally, improvements in magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting (FACS), and microfluidic technologies are making cell isolation more efficient, reproducible, and scalable. To request a free sample copy of this report,...
Post a Comment
Read more